Ann: Invex Granted Type C Meeting with FDA, page-49

invex wanted a face to face meeting and the FDA neurology have promised written response only. the significance unclear, but generally interpreted as another setback.

the FDA ophthalmology sank Invex’s hopes of 1 trial with an ophthalmology endpoint, so the market is guessing that Invex won’t have much luck with getting 1 trial with the fda neurology.

and as we’ve seen with the ASX. They prefer the FDA rather than the EMA, seeing it as traditionally the largest market despite Invex insisting that there’s a larger population to treat in the EU.